Art. 7 Regulation (EU) 2022/1646

Additional content of the national risk-based control plans and the national randomised surveillance plan

In forcesince 1 Jan 2025cited 1×
1.

The national risk-based control plans, referred to in Articles 4 and 6, and the national randomised surveillance plan, referred to in Article 5, shall specify the following:

(a)

the species to be sampled and the place of sampling;

(b)

the national legislation on the use of pharmacologically active substances and, in particular, their prohibition or their authorisation, distribution, placing on the market and administration, in so far as that legislation is not harmonised by Union legislation;

(c)

the competent authorities responsible for the implementation of the plans.

2.

The national risk-based control plans referred to in Articles 4 and 6 shall, in addition to the information specified in paragraph 1, provide the following:

(a)

a justification for the selected substances, species, products and matrices included in the plans on the basis of the criteria listed in Annexes II and VI to Delegated Regulation (EU) 2022/1644, including a justification on how the criteria listed in those Annexes were taken into account, even if no changes were made compared to the plans of the previous year;

(b)

a justification on how cases of non-compliance in the relevant Member State detected in the previous three calendar years were taken into account for optimising the plans.

Member States are not required to submit information already provided in the general part of MANCPs in accordance with Article 110(2) of Regulation (EU) 2017/625.

  • Regulation (EU) 2024/2563Lawamends

    В съответствие с член 7, параграф 1, буква г) от Регламент за изпълнение (ЕС) 2022/1646 на Комисията [Регламент за изпълнение (ЕС) 2022/1646 на …